Detail akcie MABION online

Business Summary: Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Mabion SA revenues decreased 91% to PLN6M. Net loss totaled PLN30.7M vs. income of PLN27.8M. Revenues reflect Sale of Products decrease of 91% to PLN5.7M, Leasing decrease from PLN1.5M to PLN0K, Sales of Materials decrease of 64% to PLN305K. Net loss reflects Foreign Exchange Gain decrease from PLN5.8M (income) to PLN0K, Foreign Exchange Loss increase from PLN0K to PLN1.9M (expense).